Charles River Laboratories International, Inc.

As the improvements made possible with artificial intelligence and machine learning for biopharmaceutical research and development become clear, deal making in the space has skyrocketed. S&P Global pr

Supposedly Defensive Investments The biotech sector goes through boom and bust. I describe the period in the aftermath of a biotech bubble as a ‘wilderness period’, during which stock prices stagnate,

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Boehringer Ingelheim Acquires Nerio The

While hundreds of millions around the world were celebrating the Lunar New Year of the wood dragon, a quiet shift and new reality was settling in in the Chinese biotech sector. The country's largest c